Keywords: Boehrnger Ingelheim, Pradaxa, UK, NICE, Cost effectiveness, Stroke prevention

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

Article | 01 November 2011

Print This

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute of Health and Clinical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in